Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection.

PubWeight™: 0.89‹?›

🔗 View Article (PMC 3372146)

Published in J Clin Microbiol on March 21, 2012

Authors

Maile Y Karris1, Christy M Anderson, Sheldon R Morris, Davey M Smith, Susan J Little

Author Affiliations

1: Division of Infectious Diseases, University of California, San Diego, La Jolla, California, USA. m1young@ucsd.edu

Articles cited by this

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18

Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep (2006) 37.28

Estimation of HIV incidence in the United States. JAMA (2008) 21.27

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08

Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr (2005) 15.14

Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66

HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol (2010) 7.72

High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70

HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57

The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64

Statistical analysis of repeated measures data using SAS procedures. J Anim Sci (1998) 5.45

Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr (1994) 4.81

Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr (2010) 4.32

Towards an understanding of sexual risk behavior in people living with HIV: a review of social, psychological, and medical findings. AIDS (2002) 4.27

Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80

The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 3.75

Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis (2011) 3.16

Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69

Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67

Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51

Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS (2002) 2.33

Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med (2010) 2.28

Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol (2009) 2.18

Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr (2006) 2.15

Results of the Expanded HIV Testing Initiative--25 jurisdictions, United States, 2007-2010. MMWR Morb Mortal Wkly Rep (2011) 2.15

Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility. AIDS (1999) 2.15

The detection of acute HIV infection. J Infect Dis (2010) 2.14

The future of HIV testing. J Acquir Immune Defic Syndr (2010) 1.87

Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med (2009) 1.83

Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS (2004) 1.82

Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods (2007) 1.65

Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr (2009) 1.46

Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med (2010) 1.37

Detection of acute HIV infection: we can't close the window. J Infect Dis (2011) 1.32

Secondary prevention of HIV in the United States: past, current, and future perspectives. J Acquir Immune Defic Syndr (2010) 1.29

Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS (2009) 1.22

Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods (2005) 1.14

Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-combination antiretroviral therapy era. AIDS (2012) 1.13

Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard. J Clin Virol (2011) 1.03

The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. Transfusion (2010) 1.03

Cost-effectiveness of HIV screening of blood donations in Accra (Ghana). Value Health (2008) 1.01

Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples. Transfus Med (2009) 0.99

Applying linear mixed models to estimate reliability in clinical trial data with repeated measurements. Control Clin Trials (2004) 0.98

HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. PLoS One (2011) 0.94

Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test and identification of rare polymorphisms potentially affecting assay performance. J Clin Microbiol (2010) 0.88

Infectious disease screening of blood specimens collected post-mortem provides comparable results to pre-mortem specimens. Cell Tissue Bank (2011) 0.77

Articles by these authors

Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93

Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83

Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54

Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis (2013) 2.45

Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26

HIV superinfection. J Infect Dis (2005) 2.20

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08

Disparities in smoke-free workplace policies among food service workers. J Occup Environ Med (2004) 2.08

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology (2006) 2.07

Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis (2012) 1.99

Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92

A public health model for the molecular surveillance of HIV transmission in San Diego, California. AIDS (2009) 1.81

Serosorting can potentially increase HIV transmissions. AIDS (2007) 1.78

Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77

The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76

Transmission behaviors of recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr (2006) 1.73

Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis (2010) 1.71

The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS (2015) 1.68

The global transmission network of HIV-1. J Infect Dis (2013) 1.68

Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection. J Acquir Immune Defic Syndr (2006) 1.66

Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis (2007) 1.64

Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60

Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract. AIDS (2013) 1.60

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell (2013) 1.59

Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. J Infect Dis (2007) 1.59

Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS (2008) 1.55

Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol (2011) 1.55

Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr (2011) 1.54

Characterizing HIV transmission networks across the United States. Clin Infect Dis (2012) 1.54

Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis (2013) 1.53

HIV drug resistance acquired through superinfection. AIDS (2005) 1.52

Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS (2003) 1.52

Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol (2005) 1.52

Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46

Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol (2011) 1.44

The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS (2009) 1.37

Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr (2010) 1.36

Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico. J Acquir Immune Defic Syndr (2011) 1.31

Factors associated with drug-related harms related to policing in Tijuana, Mexico. Harm Reduct J (2011) 1.31

Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal (2012) 1.31

The effect of cigarette price increases on smoking cessation in California. Prev Sci (2008) 1.30

Neurocognitive functioning in acute or early HIV infection. J Neurovirol (2010) 1.27

ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2012) 1.25

Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis (2008) 1.19

Identifying the HIV transmission bridge: which men are having unsafe sex with female sex workers and with their own wives or steady partners? J Acquir Immune Defic Syndr (2012) 1.16

Association between home smoking restrictions and changes in smoking behaviour among employed women. J Epidemiol Community Health (2006) 1.16

Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav (2014) 1.15

Malaria diagnosis by a polymerase chain reaction-based assay using a pooling strategy. Am J Trop Med Hyg (2009) 1.15

Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr (2008) 1.14

Sexual behavior of female sex workers and access to condoms in Kenya and Uganda on the Trans-Africa highway. AIDS Behav (2008) 1.14

Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis (2013) 1.13

Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA. J Infect Dis (2012) 1.10

Clinical, virologic, and immunologic correlates of HIV-1 intraclade B dual infection among men who have sex with men. AIDS (2012) 1.10

Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS (2013) 1.10

Signs or Symptoms of Acute HIV Infection in a Cohort Undergoing Community-Based Screening. Emerg Infect Dis (2016) 1.09

HIV evolution and escape. Trans Am Clin Climatol Assoc (2004) 1.09

Do changes in cigarette design influence the rise in adenocarcinoma of the lung? Cancer Causes Control (2010) 1.09

Using phylogeography to characterize the origins of the HIV-1 subtype F epidemic in Romania. Infect Genet Evol (2011) 1.07

HIV-1 clade B pol evolution following primary infection. PLoS One (2013) 1.07

Clear Links Between Starting Methamphetamine and Increasing Sexual Risk Behavior: A Cohort Study Among Men Who Have Sex With Men. J Acquir Immune Defic Syndr (2016) 1.07

Phylogenetic relatedness of HIV-1 donor and recipient populations. J Infect Dis (2013) 1.05

Risk Factors for Acute and Early HIV Infection Among Men Who Have Sex With Men (MSM) in San Diego, 2008 to 2014: A Cohort Study. Medicine (Baltimore) (2015) 1.05

Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol (2012) 1.03

Associations between substance use, erectile dysfunction medication and recent HIV infection among men who have sex with men. AIDS Behav (2007) 1.03